← Back to Skills Marketplace
hanxueyuan

Biogen Inc

by hanxueyuan · GitHub ↗ · v1.0.0 · MIT-0
cross-platform ✓ Security Clean
67
Downloads
0
Stars
0
Active Installs
1
Versions
Install in OpenClaw
/install biogen-inc
Description
专注神经科学创新,开发多发性硬化症和阿尔茨海默症药物,拥有领先基因技术和全球药品销售网络。
README (SKILL.md)

Biogen

概述

神经科学领域生物技术领军者,开发了首个多发性硬化症口服药物,在阿尔茨海默症领域引起巨大争议。

历史时间线

  • 1978年 | 在瑞士日内瓦由多位分子生物学家联合创立
  • 1980年代 | 开发干扰素和乙肝疫苗
  • 2001年 | 与Elan合作开发多发性硬化症药物Tysabri
  • 2004年 | Tysabri获批,但因PML风险暂停后重新上市
  • 2016年 | Spinraza(脊髓性肌萎缩症基因治疗)获批
  • 2021年 | Aduhelm(阿尔茨海默症药物)获FDA加速批准,引发巨大争议
  • 2023年 | Leqembi(与卫材合作)获批,阿尔茨海默症治疗新里程碑
  • 2024年 | 聚焦神经退行性疾病管线

商业模式

专注神经科学的生物制药公司,核心产品包括Tecfidera/Vumerity(多发性硬化症)、Spinraza(SMA)、Leqembi(阿尔茨海默症,与卫材合作)。通过差异化创新药物获得高定价权。

护城河分析

神经科学领域深度积累(MS药物全球领先)、与学术机构的紧密合作、独特的基因反义技术平台、患者社群和品牌忠诚度。面临仿制药竞争和管线集中的风险。

关键数据

2024年营收约100亿美元,员工约9000人,研发支出约20亿美元,在50+国家运营。

有趣事实

  • Biogen的名字来源于'Biological'和'Generation'的组合,反映了其创始人的愿景:用生物技术'生成'新的治疗方法。
  • Aduhelm的批准是FDA历史上最具争议的决定之一——三位独立顾问委员会成员因不满审批过程而辞职抗议。
Usage Guidance
This skill appears safe from a security standpoint because it is read-only content and requests no credentials or installs. Consider that the source is listed as unknown and there is no homepage — verify any facts you plan to act on (dates, drug approvals, financial figures) against authoritative sources before using the information for decisions, especially clinical or financial ones. If you expect up-to-date or citable data, prefer skills or sources that provide provenance or links to primary documents.
Capability Analysis
Type: OpenClaw Skill Name: biogen-inc Version: 1.0.0 The skill bundle contains purely informational content regarding Biogen Inc., including its history, business model, and key data. There is no executable code, network activity, or prompt injection attempts within SKILL.md or _meta.json.
Capability Assessment
Purpose & Capability
The name/description state a company overview and the SKILL.md provides a company timeline, business analysis, and facts — there are no unrelated requirements or capabilities requested.
Instruction Scope
SKILL.md is content (summary, timeline, analysis) for the agent to read/use. It does not instruct the agent to run shell commands, access files, or exfiltrate data, nor does it reference environment variables or external endpoints.
Install Mechanism
No install spec and no code files are present. This instruction-only skill will not write files or download artifacts during install.
Credentials
The skill declares no required environment variables, credentials, or config paths — proportional for a read-only informational skill.
Persistence & Privilege
Skill is not always-on (always: false) and is user-invocable; model invocation is allowed (the platform default) but this poses no extra risk given the skill has no install or credential access.
How to Use
  1. Make sure OpenClaw is installed (local or Docker)
  2. Run the install command in chat: /install biogen-inc
  3. After installation, invoke the skill by name or use /biogen-inc
  4. Provide required inputs per the skill's parameter spec and get structured output
Version History
v1.0.0
- 初始版本发布,聚焦Biogen神经科学领域的地位及创新药物发展。 - 详细梳理公司历史时间线,涵盖多发性硬化症及阿尔茨海默症药物的里程碑事件。 - 分析商业模式、护城河和市场风险。 - 提供2024年关键经营数据和有趣事实,便于快速了解公司核心。
Metadata
Slug biogen-inc
Version 1.0.0
License MIT-0
All-time Installs 0
Active Installs 0
Total Versions 1
Frequently Asked Questions

What is Biogen Inc?

专注神经科学创新,开发多发性硬化症和阿尔茨海默症药物,拥有领先基因技术和全球药品销售网络。 It is an AI Agent Skill for Claude Code / OpenClaw, with 67 downloads so far.

How do I install Biogen Inc?

Run "/install biogen-inc" in the OpenClaw or Claude Code chat to install it in one step — no extra setup required.

Is Biogen Inc free?

Yes, Biogen Inc is completely free, licensed under MIT-0. You can download, install and use it at no cost.

Which platforms does Biogen Inc support?

Biogen Inc is cross-platform and runs anywhere OpenClaw / Claude Code is available (cross-platform).

Who created Biogen Inc?

It is built and maintained by hanxueyuan (@hanxueyuan); the current version is v1.0.0.

💬 Comments